Phase i trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome Academic Article uri icon


MeSH Major

  • Leukemia, Myeloid
  • Myelodysplastic Syndromes
  • Pyridines
  • Pyrimidines


  • There is no effective treatment for relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We conducted a phase I dose escalation trial of SAR103168, a novel multi-targeted kinase inhibitor with activity against the Src kinase family, the BCR-Abl kinase and several angiogenic receptor kinases. Twenty-nine patients 18-83 years old were treated with SAR103168. Pharmacokinetics was characterized by plasma peak concentration (Cmax) at the end of the infusion, followed by a biphasic decline in the elimination profile. Adverse events were as expected for the patient population and there were no individual toxicities specific to SAR103168. Due to the unpredictable nature of drug exposure, the sponsor decided to discontinue the study prior to reaching the maximum tolerated dose.

publication date

  • January 2015



  • Academic Article



  • eng

PubMed Central ID

  • PMC5495021

Digital Object Identifier (DOI)

  • 10.3109/10428194.2014.918970

PubMed ID

  • 24794806

Additional Document Info

start page

  • 395

end page

  • 400


  • 56


  • 2